Michael A Rosenberg1,2, Molly M Shores3, Alvin M Matsumoto4,5, Petra Bůžková6, Leslie A Lange2, Richard A Kronmal6, Susan R Heckbert7, Kenneth J Mukamal8. 1. Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado. 2. Division of Biomedical Informatics and Personalized Medicine, University of Colorado School of Medicine, Aurora, Colorado. 3. Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, VA Puget Sound Health Care System, Washington. 4. Geriatric Research, Education, and Clinical Center, Department of Veterans Affairs Puget Sound Health Care System, Washington. 5. Division of Gerontology and Geriatric Medicine, Department of Medicine, University of Washington School of Medicine, Seattle, Washington. 6. Department of Biostatistics, University of Washington, Seattle. 7. Department of Epidemiology, University of Washington, Seattle. 8. Department of General Medicine and Primary Care, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Abstract
BACKGROUND: Decline in serum androgens is common among older men and has been associated with cardiovascular disease, although its role in risk of atrial fibrillation (AF) has not been well defined. HYPOTHESIS: Low serum androgens are associated with an increased risk of AF. METHODS: We examined the prospective associations between testosterone, its more active metabolite dihydrotestosterone (DHT), and sex hormone-binding globulin (SHBG) with risk of AF among 1019 otherwise healthy men with average age 76.3 ±4.9 years in the Cardiovascular Health Study. RESULTS: After median follow-up of 9.5 years, 304 (30%) men developed AF. We detected a nonlinear association with risk of incident AF in both free and total DHT, in which subjects with the lowest levels had a higher risk of incident AF. After adjustment for demographics, clinical risk factors, left atrial diameter, and serum NT-proBNP levels, men with free DHT <0.16 ng/dL were at increased risk compared with men with higher levels (hazard ratio: 1.48, 95% confidence interval: 1.01-2.17, P <0.05). Sensitivity analyses confirmed that the increased risk was not cutpoint-specific, with a significant association noted up to cutpoints <~0.2 ng/dL. We also detected a complex nonlinear association between SHBG and incident AF, in which subjects in the middle quintile (52.9-65.3 nmol/L) had increased risk. CONCLUSIONS: Among older men, low free DHT is associated with an increased risk of incident AF. Further studies are needed to explore mechanisms for this association.
BACKGROUND: Decline in serum androgens is common among older men and has been associated with cardiovascular disease, although its role in risk of atrial fibrillation (AF) has not been well defined. HYPOTHESIS: Low serum androgens are associated with an increased risk of AF. METHODS: We examined the prospective associations between testosterone, its more active metabolite dihydrotestosterone (DHT), and sex hormone-binding globulin (SHBG) with risk of AF among 1019 otherwise healthy men with average age 76.3 ±4.9 years in the Cardiovascular Health Study. RESULTS: After median follow-up of 9.5 years, 304 (30%) men developed AF. We detected a nonlinear association with risk of incident AF in both free and total DHT, in which subjects with the lowest levels had a higher risk of incident AF. After adjustment for demographics, clinical risk factors, left atrial diameter, and serum NT-proBNP levels, men with free DHT <0.16 ng/dL were at increased risk compared with men with higher levels (hazard ratio: 1.48, 95% confidence interval: 1.01-2.17, P <0.05). Sensitivity analyses confirmed that the increased risk was not cutpoint-specific, with a significant association noted up to cutpoints <~0.2 ng/dL. We also detected a complex nonlinear association between SHBG and incident AF, in which subjects in the middle quintile (52.9-65.3 nmol/L) had increased risk. CONCLUSIONS: Among older men, low free DHT is associated with an increased risk of incident AF. Further studies are needed to explore mechanisms for this association.
Authors: L P Fried; N O Borhani; P Enright; C D Furberg; J M Gardin; R A Kronmal; L H Kuller; T A Manolio; M B Mittelmark; A Newman Journal: Ann Epidemiol Date: 1991-02 Impact factor: 3.797
Authors: Matthew J Budoff; Susan S Ellenberg; Cora E Lewis; Emile R Mohler; Nanette K Wenger; Shalender Bhasin; Elizabeth Barrett-Connor; Ronald S Swerdloff; Alisa Stephens-Shields; Jane A Cauley; Jill P Crandall; Glenn R Cunningham; Kristine E Ensrud; Thomas M Gill; Alvin M Matsumoto; Mark E Molitch; Rine Nakanishi; Negin Nezarat; Suguru Matsumoto; Xiaoling Hou; Shehzad Basaria; Susan J Diem; Christina Wang; Denise Cifelli; Peter J Snyder Journal: JAMA Date: 2017-02-21 Impact factor: 56.272
Authors: Jeffrey L Anderson; Heidi T May; Donald L Lappé; Tami Bair; Viet Le; John F Carlquist; Joseph B Muhlestein Journal: Am J Cardiol Date: 2015-12-13 Impact factor: 2.778
Authors: Molly M Shores; Alice M Arnold; Mary L Biggs; W T Longstreth; Nicholas L Smith; Jorge R Kizer; Anne R Cappola; Calvin H Hirsch; Brett T Marck; Alvin M Matsumoto Journal: Clin Endocrinol (Oxf) Date: 2014-05-05 Impact factor: 3.478
Authors: Petter K Nyström; Axel C Carlsson; Karin Leander; Ulf de Faire; Mai-Lis Hellenius; Bruna Gigante Journal: PLoS One Date: 2015-05-15 Impact factor: 3.240
Authors: Michael A Rosenberg; Molly M Shores; Alvin M Matsumoto; Petra Bůžková; Leslie A Lange; Richard A Kronmal; Susan R Heckbert; Kenneth J Mukamal Journal: Clin Cardiol Date: 2018-06-08 Impact factor: 2.882
Authors: Dylan Berger; Aaron R Folsom; Pamela J Schreiner; Lin Y Chen; Erin D Michos; Wesley T O'Neal; Elsayed Z Soliman; Alvaro Alonso Journal: Maturitas Date: 2019-03-31 Impact factor: 4.342
Authors: Peng Hu; Jun Huang; Yi Lu; Murui Zheng; Haiyi Li; Xueru Duan; Hai Deng; Wenjing Zhao; Xudong Liu Journal: Front Cardiovasc Med Date: 2022-08-22